最新消息

HanchorBio announced the successful completion of its latest Scientific Advisory Board (SAB) meeting. Chaired by Professor Mingyi Chen (UT Southwestern Medical Center), the SAB brings together global leaders from institutions such as The Ohio State University, University of Michigan, Tsinghua University, and National Taiwan University to review HanchorBio’s clinical progress, translational insights, and pipeline strategy across oncology and autoimmune diseases.

Showcase the Broad Therapeutic Potential of HCB101 in Tumor Immunotherapy *As the only innovative drug company from Taiwan invited to this year’s CBA Annual Conference, HanchorBio took the international stage to present its AI-assisted Structural Engineering on SIRP-alfa fusion biologic for enhancing Safety and Efficacy, marking an important milestone for Taiwan’s biotech industry.” *This recognition not only strengthens Taiwan’s position in global AI-assisted drug development, but also opens new opportunities for cross-border licensing and collaboration.

HanchorBio Inc. completed a face-to-face Scientific Advisory Board (SAB) meeting on March 29, 2023, in Taipei, Taiwan withworld-renowned professors and few Board of Director (BOD) members.漢康生技（HanchorBio Inc.）於2023年3月29日在台北內湖總部成功舉辦了(SAB)科學顧問委員會會議。